Hydrocortisone granules in capsules for opening (Alkindi) as replacement therapy in pediatric patients with adrenal insufficiency

ABSTRACT Introduction Treatment of pediatric adrenal insufficiency (AI) has been challenging due to a lack of dose and age appropriate hydrocortisone preparations for children. Hydrocortisone granules in capsules for opening (Alkindi) is the only licensed replacement therapy specifically designed for use in pediatric adrenal insufficiency. Areas Covered The high unmet need of the pediatric AI patient population for a licensed, dose-appropriate hydrocortisone formulation and the development and approval of hydrocortisone granules in capsules for opening for pediatric AI. Expert opinion To date, treatment of children with AI has relied on parents or pharmacists crushing tablets of hydrocortisone. Pediatric patients have suffered from over- and under-treatment with poor health outcomes. Hydrocortisone granules in capsules for opening provides accurate, age-appropriate dosing, allowing appropriate dose titration for the growing child. The granule-based formulation is taste masked to hide the bitterness of hydrocortisone, and in clinical trials was well tolerated and easily administered to children. The granules can be administered either directly to the mouth or sprinkled onto soft food or yogurt. Hydrocortisone granules in capsules for opening provides the first licensed treatment option specifically designed for pediatric patients with AI.

[1]  S. Klein,et al.  A Biopredictive In Vitro Approach for Assessing Compatibility of a Novel Pediatric Hydrocortisone Drug Product within Common Pediatric Dosing Vehicles , 2020, Pharmaceutical Research.

[2]  S. Wiegand,et al.  A Prospective Study of Children Aged 0–8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules , 2020, The Journal of clinical endocrinology and metabolism.

[3]  R. Brundage,et al.  Manipulation of Hydrocortisone Tablets Leads to Iatrogenic Cushing Syndrome in a 6-Year-Old Girl With CAH , 2020, Journal of the Endocrine Society.

[4]  H. Falhammar,et al.  Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd‐LIFE study , 2019, Clinical endocrinology.

[5]  R. Ross,et al.  Hydrocortisone Granules Are Bioequivalent When Sprinkled Onto Food or Given Directly on the Tongue , 2019, Journal of the Endocrine Society.

[6]  O. Eyal,et al.  Adrenal crises in children with adrenal insufficiency: epidemiology and risk factors , 2019, European Journal of Pediatrics.

[7]  B. Keevil,et al.  Accuracy of hydrocortisone dose administration via nasogastric tube , 2018, Clinical endocrinology.

[8]  S. Klein,et al.  Biorelevant in vitro assessment of dissolution and compatibility properties of a novel paediatric hydrocortisone drug product following exposure of the drug product to child‐appropriate administration fluids , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  S. Dixon,et al.  Adrenal Insufficiency in Young Children: a Mixed Methods Study of Parents’ Experiences , 2018, Journal of Genetic Counseling.

[10]  H. Batchelor,et al.  How close is the dose? Manipulation of 10mg hydrocortisone tablets to provide appropriate doses to children , 2018, International journal of pharmaceutics.

[11]  A. Mallappa,et al.  Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia , 2018, The Journal of clinical endocrinology and metabolism.

[12]  B. Keevil,et al.  Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone , 2018, Journal of bioequivalence & bioavailability.

[13]  S. Sugihara,et al.  Incidence and Characteristics of Adrenal Crisis in Children Younger than 7 Years with 21-Hydroxylase Deficiency: A Nationwide Survey in Japan , 2018, Hormone Research in Paediatrics.

[14]  S. Wiegand,et al.  Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency , 2018, Clinical endocrinology.

[15]  Matthew Roberts,et al.  Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing , 2018, BMJ Paediatrics Open.

[16]  R. V. van Wagoner,et al.  Iatrogenic Cushing Syndrome in a Child With Congenital Adrenal Hyperplasia: Erroneous Compounding of Hydrocortisone , 2018, The Journal of clinical endocrinology and metabolism.

[17]  Zinnia P. Parra-Guillen,et al.  Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults , 2018, Clinical Pharmacokinetics.

[18]  C. Kloft,et al.  Quality of compounded hydrocortisone capsules used in the treatment of children. , 2017, European journal of endocrinology.

[19]  O. Porzio,et al.  HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[20]  H. Batchelor,et al.  COMPARISON OF HYDROCORTISONE 10 MG TABLETS: TABLET HARDNESS OPTIMISED FOR ADULT USE HAS NEGATIVE CONSEQUENCES FOR PAEDIATRIC USE , 2016, Archives of Disease in Childhood.

[21]  H. Dörr,et al.  Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life. , 2016, European journal of endocrinology.

[22]  Stefan R Bornstein,et al.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[23]  D. V. van Riet-Nales,et al.  Methods of administering oral formulations and child acceptability. , 2015, International journal of pharmaceutics.

[24]  D. Eckland,et al.  Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. , 2015, The Journal of clinical endocrinology and metabolism.

[25]  H. Falhammar,et al.  Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2014, The Journal of clinical endocrinology and metabolism.

[26]  J. Himes,et al.  Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort. , 2014, The Journal of pediatrics.

[27]  B. Walker,et al.  Treatment and health outcomes in adults with congenital adrenal hyperplasia , 2014, Nature Reviews Endocrinology.

[28]  A. Cavalcanti,et al.  Erosive and cariogenicity potential of pediatric drugs: study of physicochemical parameters , 2013, BMC oral health.

[29]  M. Dattani,et al.  Deconvolution analysis of 24‐h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy , 2011, Clinical endocrinology.

[30]  M. Nishitani,et al.  Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. , 2012, The Journal of clinical endocrinology and metabolism.

[31]  A. Mullen,et al.  Paediatric nurses' knowledge and practice of mixing medication into foodstuff , 2012, The International journal of pharmacy practice.

[32]  P. Hindmarsh,et al.  Incidence and clinical features of congenital adrenal hyperplasia in Great Britain , 2012, Archives of Disease in Childhood.

[33]  G. Burmester,et al.  Exogenous and endogenous glucocorticoids in rheumatic diseases. , 2011, Arthritis and rheumatism.

[34]  V. Montori,et al.  Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. , 2010, The Journal of clinical endocrinology and metabolism.

[35]  V. Montori,et al.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.

[36]  G. Luef,et al.  Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction , 2010, Archives of Disease in Childhood.

[37]  Ahmet Uçaktürk,et al.  Adverse Effect of Phenytoin on Glucocorticoid Replacement in a Child with Adrenal Insufficiency , 2010, Journal of pediatric endocrinology & metabolism : JPEM.

[38]  P. Pagel,et al.  Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. , 2009, The Journal of clinical endocrinology and metabolism.

[39]  M. Mclean,et al.  Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency , 2007, Pediatrics.

[40]  F. Sweep,et al.  Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. , 2007, The Journal of clinical endocrinology and metabolism.

[41]  P. Gardiner,et al.  Promoting medication adherence in children. , 2006, American family physician.

[42]  J. Popović,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2005, Journal for specialists in pediatric nursing : JSPN.

[43]  C. Deal,et al.  Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. , 2005, The Journal of clinical endocrinology and metabolism.

[44]  W. Oyen,et al.  Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. , 2003, The Journal of clinical endocrinology and metabolism.

[45]  G. Chrousos,et al.  Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. , 2001, The Journal of clinical endocrinology and metabolism.

[46]  B. Walker,et al.  Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases. , 1999, The Journal of clinical endocrinology and metabolism.

[47]  R. Carey,et al.  Adrenal insufficiency. , 1997, Current therapy in endocrinology and metabolism.

[48]  V. Kyriazopoulou,et al.  Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. , 1984, The Journal of clinical endocrinology and metabolism.